Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related ...

The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease.

Viking Therapeutics announced the start of Phase 3 studies involving its injectable, GLP-1/GIP-targeted obesity drug, called ...

Gilmore O’Neill’s exit from Biogen comes at a particularly inopportune moment for the company, which is testing a potential Alzheimer’s treatment in late-stage studies. 40 years later ...

Biogen’s Aduhelm, Sarepta’s Exondys 51, along with Covis Pharma’s Makena were all cleared quickly by the US Food and Drug Administration despite weak evidence and disagreements among reviewers, ...

Biogen Inc. is making good on its promise to focus on “external opportunities,” this time with a new deal involving a Bedford-based biotech. Boston Business Journal. Select a City ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Crispr Therapeutics AG (CRSP – Research Report ...

Sarepta said continued approval of the gene therapy may hinge on evidence from a ... But it drew criticism in 2021 after the FDA cleared Biogen’s controversial Alzheimer’s drug ...

Early last year, Biogen pulled the plug on the treatment. Biogen FDA Office of Inspector General (OIG) Department of Health and Human Services (HHS) accelerated approval Sarepta Makena Exondys 51 ...

Sarepta said it is "fully committed" to completing the trial for Exondys and attributes the delays to a variety of factors including ... Biogen Inc.'s Alzheimer's drug Aduhelm may be the best ...

The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease.

Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal watchdogs said in a report.